These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
677 related articles for article (PubMed ID: 25108151)
1. cRGD-directed, NIR-responsive and robust AuNR/PEG-PCL hybrid nanoparticles for targeted chemotherapy of glioblastoma in vivo. Zhong Y; Wang C; Cheng R; Cheng L; Meng F; Liu Z; Zhong Z J Control Release; 2014 Dec; 195():63-71. PubMed ID: 25108151 [TBL] [Abstract][Full Text] [Related]
2. Gold nanorod-cored biodegradable micelles as a robust and remotely controllable doxorubicin release system for potent inhibition of drug-sensitive and -resistant cancer cells. Zhong Y; Wang C; Cheng L; Meng F; Zhong Z; Liu Z Biomacromolecules; 2013 Jul; 14(7):2411-9. PubMed ID: 23701318 [TBL] [Abstract][Full Text] [Related]
3. cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo. Zhu Y; Zhang J; Meng F; Deng C; Cheng R; Feijen J; Zhong Z J Control Release; 2016 Jul; 233():29-38. PubMed ID: 27178807 [TBL] [Abstract][Full Text] [Related]
4. Targeted glioma chemotherapy by cyclic RGD peptide-functionalized reversibly core-crosslinked multifunctional poly(ethylene glycol)-b-poly(ε-caprolactone) micelles. Fang Y; Jiang Y; Zou Y; Meng F; Zhang J; Deng C; Sun H; Zhong Z Acta Biomater; 2017 Mar; 50():396-406. PubMed ID: 28065871 [TBL] [Abstract][Full Text] [Related]
5. Cyclo(RGD)-Decorated Reduction-Responsive Nanogels Mediate Targeted Chemotherapy of Integrin Overexpressing Human Glioblastoma In Vivo. Chen W; Zou Y; Zhong Z; Haag R Small; 2017 Feb; 13(6):. PubMed ID: 27865044 [TBL] [Abstract][Full Text] [Related]
6. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo. Gu X; Wei Y; Fan Q; Sun H; Cheng R; Zhong Z; Deng C J Control Release; 2019 May; 301():110-118. PubMed ID: 30898610 [TBL] [Abstract][Full Text] [Related]
7. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560 [TBL] [Abstract][Full Text] [Related]
8. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells. Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942 [TBL] [Abstract][Full Text] [Related]
9. Near-infrared light-triggered thermochemotherapy of cancer using a polymer-gold nanorod conjugate. Ko H; Son S; Bae S; Kim JH; Yi GR; Park JH Nanotechnology; 2016 Apr; 27(17):175102. PubMed ID: 26987360 [TBL] [Abstract][Full Text] [Related]
10. Zwitterionic nanoparticles constructed from bioreducible RAFT-ROP double head agent for shell shedding triggered intracellular drug delivery. Huang P; Liu J; Wang W; Zhang Y; Zhao F; Kong D; Liu J; Dong A Acta Biomater; 2016 Aug; 40():263-272. PubMed ID: 26607767 [TBL] [Abstract][Full Text] [Related]
11. Construction of Small-Sized, Robust, and Reduction-Responsive Polypeptide Micelles for High Loading and Targeted Delivery of Chemotherapeutics. Xue S; Gu X; Zhang J; Sun H; Deng C; Zhong Z Biomacromolecules; 2018 Aug; 19(8):3586-3593. PubMed ID: 30025206 [TBL] [Abstract][Full Text] [Related]
12. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma. Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485 [TBL] [Abstract][Full Text] [Related]
13. A dual pH/thermal responsive nanocarrier for combined chemo-thermotherapy based on a copper-doxorubicin complex and gold nanorods. Lei M; Ma M; Pang X; Tan F; Li N Nanoscale; 2015 Oct; 7(38):15999-6011. PubMed ID: 26370706 [TBL] [Abstract][Full Text] [Related]
14. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo. Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029 [TBL] [Abstract][Full Text] [Related]
15. Glyco-nanoparticles with sheddable saccharide shells: a unique and potent platform for hepatoma-targeting delivery of anticancer drugs. Chen W; Zou Y; Meng F; Cheng R; Deng C; Feijen J; Zhong Z Biomacromolecules; 2014 Mar; 15(3):900-7. PubMed ID: 24460130 [TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659 [TBL] [Abstract][Full Text] [Related]
17. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Yin P; Wang Y; Qiu Y; Hou L; Liu X; Qin J; Duan Y; Liu P; Qiu M; Li Q Int J Nanomedicine; 2012; 7():3961-9. PubMed ID: 22888239 [TBL] [Abstract][Full Text] [Related]
18. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo. Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618 [TBL] [Abstract][Full Text] [Related]
19. Environmentally Self-Adaptative Nanocarriers Suppress Glioma Proliferation and Stemness via Codelivery of shCD163 and Doxorubicin. Liu J; Zhang Y; Chen T; Chen H; He H; Jin T; Wang J; Ke Y ACS Appl Mater Interfaces; 2020 Nov; 12(47):52354-52369. PubMed ID: 33196179 [TBL] [Abstract][Full Text] [Related]
20. Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug. Lee BS; Park K; Park S; Kim GC; Kim HJ; Lee S; Kil H; Oh SJ; Chi D; Kim K; Choi K; Kwon IC; Kim SY J Control Release; 2010 Oct; 147(2):253-60. PubMed ID: 20624433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]